iBio opened higher at $0.83, compared with its previous close of $0.82. In the last trading session, the stock traded between $0.77 and $0.83. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in iBio is now worth
$ 0.20
Resulting in a loss of
$ 99.80 (99.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.06 (-7.30%)
Day High
$0.83
Day Low
$0.77
Day Open
$0.83
Prev Close
$0.82
Volume
2,75,862
1W Return
-4.50%
1M Return
-15.58%
3M Return
-48.20%
6M Return
-53.98%
1Y Return
-38.39%
Fundamentals
Market Cap ($ Mn)
54
PE Ratio
-
PB Ratio
0.79
PEG Ratio
-
ROE
-115.97%
ROCE
-99.25%
EPS (TTM)
$-0.31
Investment Returns
1 Week
-4.50%
1 Month
-15.58%
3 Months
-48.20%
6 Months
-53.98%
9 Months
-65.43%
Financials
Quarterly
All values in $ Mn
0.2
Dec 24
0.0
Mar 25
0.2
Jun 25
0.1
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
11Nov
iBio Q1FY27 loss narrows to $0.05, sales jump 975%
Loss per share narrowed to $0.05, beating consensus estimate of $0.08. Quarterly revenue surged 975% to $1.075 million from $100,000 in prior year. R&D expenses increased 87% to $6.7 million due to clinical trial activities. Completed single ascending dose phase of IBIO-600 Phase 1 trial. Cash position stands at $76.7 million as of September 30, 2026.
2 days ago
28Aug
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136%
Net loss widened 80% YoY to $33.0 million in FY26. R&D expenses surged 136% to $19.6 million due to clinical trial initiation. Cash position strengthened to $88.0 million following $126M+ in financings. Revenue declined to $0.1 million from $0.4 million in prior year. $5.0 million impairment recorded for IBIO-101 intangible assets.
2mo ago
1Jul
iBio IBIO-610 achieves 98% Activin E inhibition in obese NHP study
iBio announced new preclinical data for IBIO-610, showing 98% inhibition of active Activin E at week 4 in obese non-human primates. When combined with semaglutide, the candidate reduced lean mass loss by 73% while driving greater fat loss. The data supports a long-acting antibody approach for obesity treatment.
4mo ago
9Jun
Raymond James initiates coverage on iBio with Outperform rating
Raymond James analyst Martin Auster initiated coverage on iBio with an Outperform rating and a price target of $5, indicating a positive outlook for the stock.
